2B78:F:F-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.167

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.09 (-0.32%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.40 (-0.79%)

USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.05 (-0.08%)

USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.02 (-0.13%)

USD 54.47B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.39 (-0.39%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.15 (-0.06%)

USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 40.89B
0ZC:F Zscaler Inc

+1.08 (+0.65%)

USD 37.92B

ETFs Containing 2B78:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.55% 46% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.55% 46% F 58% F
Trailing 12 Months  
Capital Gain 18.91% 65% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.91% 65% D 65% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.43% 11% F 27% F
Dividend Return -6.43% 10% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.71% 58% F 85% B
Risk Adjusted Return -54.94% 15% F 20% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.